VERTEX PHARMACEUTICALS INC / MA Net Cash Provided by (Used in) Continuing Operations
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Net Cash Provided by (Used in) Continuing Operations of $469.18 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2017-02-23
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for the quarter ending 2015-06-30 was $205.66M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for the quarter ending 2015-03-31 was $39.62M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for the quarter ending 2014-12-31 was -$93.30M.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for the quarter ending 2014-09-30 was $298.00M, a 473.81% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for fiscal 2016 was $469.18M, a 424.17% increase from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for fiscal 2015 was $89.51M, a 59.95% increase from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for fiscal 2014 was $55.96M, a 29.96% decline from fiscal 2013.
- VERTEX PHARMACEUTICALS INC / MA net cash provided by (used in) continuing operations for fiscal 2013 was $79.89M, a 467.13% increase from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2016-12-31 | $469.18M 10-K · filed 2017-02-23 | |||
| 2015-12-31 | $89.51M 10-K · filed 2017-02-23 | |||
| 2015-06-30 | $205.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $245.28M 10-Q · filed 2015-08-04 | $151.98M derived: sum of 3 quarters · filed 2017-02-23 | $449.99M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $39.62M 10-Q · filed 2015-05-04 | -$53.68M derived: sum of 2 quarters · filed 2017-02-23 | $244.32M derived: sum of 3 quarters · filed 2017-02-23 | $240.83M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | -$93.30M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $204.70M derived: sum of 2 quarters · filed 2017-02-23 | $201.21M derived: sum of 3 quarters · filed 2017-02-23 | $55.96M 10-K · filed 2017-02-23 |
| 2014-09-30 | $298.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $294.52M derived: sum of 2 quarters · filed 2015-08-04 | $149.26M 10-Q · filed 2014-11-06 | $135.38M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | -$3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | -$148.74M 10-Q · filed 2015-08-04 | -$162.62M derived: sum of 3 quarters · filed 2016-02-16 | -$110.69M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | -$145.25M 10-Q · filed 2015-05-04 | -$159.14M derived: sum of 2 quarters · filed 2016-02-16 | -$107.20M derived: sum of 3 quarters · filed 2016-02-16 | $44.95M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | -$13.88M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $38.05M derived: sum of 2 quarters · filed 2016-02-16 | $190.20M derived: sum of 3 quarters · filed 2016-02-16 | $79.89M 10-K · filed 2016-02-16 |
| 2013-09-30 | $51.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $204.08M derived: sum of 2 quarters · filed 2014-11-06 | $93.77M 10-Q · filed 2014-11-06 | $146.29M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $152.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $41.84M 10-Q · filed 2014-07-31 | $94.36M derived: sum of 3 quarters · filed 2015-02-13 | $77.19M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | -$110.31M 10-Q · filed 2014-05-05 | -$57.79M derived: sum of 2 quarters · filed 2015-02-13 | -$74.96M derived: sum of 3 quarters · filed 2015-02-13 | $111.18M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $52.52M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $35.35M derived: sum of 2 quarters · filed 2015-02-13 | $221.48M derived: sum of 3 quarters · filed 2015-02-13 | $14.09M 10-K · filed 2015-02-13 |
| 2012-09-30 | -$17.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $168.96M derived: sum of 2 quarters · filed 2013-11-07 | -$38.43M 10-Q · filed 2013-11-07 | -$105.66M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $186.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | -$21.26M 10-Q · filed 2013-08-02 | -$88.48M derived: sum of 3 quarters · filed 2014-02-11 | -$4.13M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | -$207.40M 10-Q · filed 2013-05-08 | -$274.62M derived: sum of 2 quarters · filed 2014-02-11 | -$190.27M derived: sum of 3 quarters · filed 2014-02-11 | -$178.61M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | -$67.22M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | $17.13M derived: sum of 2 quarters · filed 2014-02-11 | $28.78M derived: sum of 3 quarters · filed 2014-02-11 | $232.12M 10-K · filed 2014-02-11 |
| 2011-09-30 | $84.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $96.01M derived: sum of 2 quarters · filed 2012-11-06 | $299.35M 10-Q · filed 2012-11-06 | -$27.36M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $11.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $215.00M 10-Q · filed 2012-08-08 | -$111.71M derived: sum of 3 quarters · filed 2013-03-01 | |
| 2011-03-31 | $203.34M 10-Q · filed 2012-05-10 | -$123.36M derived: sum of 2 quarters · filed 2013-03-01 | ||
| 2010-12-31 | -$326.70M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$203.46M 10-K · filed 2013-03-01 | ||
| 2010-09-30 | $123.24M 10-Q · filed 2011-11-03 | |||
| 2009-12-31 | $57.54M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |